Buchang Pharmaceutical announced that the participating company Qilekang Digital Healthcare Real Holding Company, Pomegranate Yunyi, was listed on the US NASDAQ on October 8, 2025. As of September 30, 2025, the book value of the company's investment in Qilekang Digital Healthcare was 326 million yuan. As of December 31, 2025, the market value of the corresponding shares held by the company was 33.791 million yuan. It is estimated that the confirmed profit and loss from changes in fair value of -293 million yuan will reduce the company's net profit of 293 million yuan in 2025, without affecting net profit after deduction. The final data is based on the audited 2025 Annual Report.

Zhitongcaijing · 01/06 08:41
Buchang Pharmaceutical announced that the participating company Qilekang Digital Healthcare Real Holding Company, Pomegranate Yunyi, was listed on the US NASDAQ on October 8, 2025. As of September 30, 2025, the book value of the company's investment in Qilekang Digital Healthcare was 326 million yuan. As of December 31, 2025, the market value of the corresponding shares held by the company was 33.791 million yuan. It is estimated that the confirmed profit and loss from changes in fair value of -293 million yuan will reduce the company's net profit of 293 million yuan in 2025, without affecting net profit after deduction. The final data is based on the audited 2025 Annual Report.